Advances in photodynamic therapy of cancer

Current Cancer Therapy Reviews

Volumn 7, Issue 3, 2011, Pages 234-247

  de Rosa, Aniello ^a   Naviglio, Daniele ^b   Di Luccia, Aldo ^c  

^a Istituto per i Sistemi Agricoli e Forestali del Mediterraneo   (Italy)

^b UNIVERSITY OF NAPLES FEDERICO II   (Italy)

^c UNIVERSITY OF FOGGIA   (Italy)

Author keywords

Active transport; Apoprotein receptor; Cancer; Cytostatic drugs; Hematoporphyrins; LDL; Photodynamic therapy

Indexed keywords

AMINOLEVULINIC ACID; AMINOLEVULINIC ACID METHYL ESTER; CARBOPLATIN; CASPASE 3; CASPASE 9; CISPLATIN; CYTOCHROME C; CYTOSTATIC AGENT; EPTAPLATIN; LOBAPLATIN; LOW DENSITY LIPOPROTEIN RECEPTOR; NEDAPLATIN; PHOTOFRIN; PHOTOSENSITIZING AGENT; PORPHYRIN; ROSTAPORFIN; TEMOPORFIN; VERTEPORFIN;

ACTINIC KERATOSIS; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; BARRETT ESOPHAGUS; BASAL CELL CARCINOMA; BLADDER CANCER; BONE MARROW SUPPRESSION; BRAIN CANCER; BRONCHUS TUMOR; CANCER THERAPY; CYTOTOXICITY; DRUG STRUCTURE; DRUG SYNTHESIS; ESOPHAGUS CANCER; GYNECOLOGIC CANCER; HEAD AND NECK CANCER; HUMAN; IN VITRO STUDY; IN VIVO STUDY; LUNG CANCER; NAUSEA; NEPHROTOXICITY; NONHUMAN; PHOTOACTIVATION; PHOTODYNAMIC THERAPY; PRIORITY JOURNAL; RECTUM CANCER; SKIN TUMOR; STOMACH CANCER; UTERINE CERVIX CANCER; VOMITING;

EID: 79959992872     PISSN: 15733947     EISSN: 18756301     Source Type: Journal    
DOI: 10.2174/157339411796234889     Document Type: Article

References (137)

1. Edelson MF: Light-activated drugs. Sci Am 1988; 68: 68-75.
2. Baden H. In: The Chemotherapy of Psoriasis, Pergamon: New York, 1984.
3. Raab O. Infusoria. Z Biol 1900; 39: 524.
4. Tappeiner H. Muench Med Wochenschr 1903; 47: 2024.
5. Meyer-Betz F. Untersuchungen uber die Biologische (photodynamische) Wirkung des Hematoporphyrins und anderer Derivative des Blut-und Galenfarbstoffs. Dtsch Arch Klin Med 1913; 112: 476-503.
6. Laurens H. The Physiological Effects of Radiation Energy. Tudor Press: New York, 1933.
7. Policard ACR. Hebd Soc Biol 1925; 91: 1422.
8. Gauvain H. Actinotherapy Technique; The Sollux Publishing Co: Slough, UK. 1933.
9. Kulms D, Poppelmann B, Yarosh D, Luger T, Krutman J, Schwartz T. Nuclear and cell membrane effects contribute independently to the induction of apoptosis in human cells exposed to ultraviolet radiation. J. Invest. Derm. 1999; 113: 438.
10. Ackroyd R, Kelty C, Brown N, et al. The history of photodetection and photodynamic therapy. Photochem Photobiol 2001; 74: 656-669.
11. Hausmann W. Die dendibilisierende Wirkung des Hematoporphyrins. Biochem Z 1911; 30: 276-316.
12. Policard A. Etudes sur les aspects offerts par des tumeurs experimentales examinees a la lumiere deWood. C R Soc Biol 1924; 91: 1423-1428.
13. Schwartz S, Absolon K, Vermund H. Some relationships of porphyrins, x-rays and tumors. Bull Minnesota Univ School Med 1955; 27: 7-13.
14. Lipson RL, Baldes EJ. The photodynamic properties of a particular hematoporphyrin derivative. Arch Dermatol 1960; 82: 508-516.
15. Lipson RL, Baldes EJ, Olsen AM. The use of a derivative of hematoporphyrin in tumor detection. J Natl Cancer Inst 1961; 26: 1-11.
16. Diamond I, Granelli SG, McDonagh AF, et al. Photodynamic therapy of malignant tumours. Lancet 1972; 2(7788): 1175-1177.
17. Figge FH, Weiland GS, Manganiello OJ. Cancer detection and therapy: affinity of neoplastic, embryonic and traumatized regenerating tissues for porphyrins and metalloporphyrins. Proc Soc Exp Biol Med 1948; 68: 640-641.
18. Manganiello LOJ, Figge FH. Cancer detection and therapy: II. Methods of preparation and biological effects of metalloporphyrins. Bull Sch Med Univ Md 1951; 36: 3-7.
19. Rassmussan-Taxdal DS, Ward GE, Figge FH. Fluorescence of human lymphatic and cancer tissues following high dose of intravenous hematoporphyrin. Cancer 1955; 8: 78-81.
20. Lipson RL, Baldes EJ, Gray MJ. Hematoporphyrin derivative for the detection and management of cancer. Cancer 1967; 20: 255-257.
21. Kyriazis GA, Balin H, Lipson RL. Hematoporphyrin derivative fluorescence test colposcopy and colpophotography in the diagnosis of atypical metaplasia, dysplasia and carcinoma in situ of the cervix uteri. Am J Obstet Gynecol 1973; 117: 375-380.
22. Dougherty TJ, Grindley GB, Fiel R, Weishaupt KR, Boyle DG. Photoradiation therapy II. Cure of animal tumors with hematoporphyrine and light. J Natl Cancer Inst 1975; 55: 115-121.
23. Dougherty TJ. Photoradiation therapy for the treatment of malignant tumors. Cancer Res 1978; 36: 2628-2635.
24. Lo Cicero J 3rd, Metzdorff M, Almgren C. Photodynamic therapy in the palliation of late stage obstructing non-small cell lung cancer. Chest 1990; 98: 97-100.
25. Balchum OJ, Doiron DR, Huth GC. Photoradiation therapy of endobronchial lung cancers employing the photodynamic action of hematoporphyrin derivative. Lasers Surg Med 1984; 4: 13-30.
26. Lam S, Muller NL, Miller RR, et al. Predicting the response of obstructive endobronchial tumors to photodynamic therapy. Cancer 1986; 58: 2298-2306.
27. Kelly JF, Snell ME, Berenbaum MC. Photodynamic destruction of human bladder carcinoma. Br J Cancer 1975; 31: 237-244.
28. Prout GR Jr, Lin CW, Benson R Jr, et al. Photodynamic therapy with hematoporphyrin derivative in the treatment of superficial transitional-cell carcinoma of the bladder. NEngl J Med 1987; 317: 1251-1255.
29. McCaughan JS Jr, Williams TE Jr, Bethel BH. Palliation of esophageal malignancy with photodynamic therapy. Ann Thorac Surg 1985; 40: 113-120.
30. Hayata Y, Kato H, Okitsu H, et al. Photodynamic therapy with hematoporphyrin derivative in cancer of the upper gastrointestinal tract. Semin Surg Oncol 1985; 1: 1-11.
31. Sibille A, Lambert R, Souquet JC, et al. Long-term survival after photodynamic therapy for esophageal cancer. Gastroenterology 1995; 108: 337-344.
32. Ward BG, Forbes IJ, Cowled PA, et al. The treatment of vaginal recurrences of gynaecological malignancy with phototherapy following hematoporphyrin derivative pre-treatment. Am J Obstet Gynecol 1982; 142: 356-357.
33. Kaye AH, Hill JS. Photodynamic therapy of brain tumours. Ann Acad Med Singapore 1993; 22(3 Suppl): 470-481.
34. Barr H, Krasner N, Boulos PB, et al. Photodynamic therapy for colorectal cancer: a quantitative pilot study. Br J Surg 1990; 77: 93-96.
35. Gomer CJ, Jester JV, Razum NJ, et al. Photodynamic therapy of intraocular tumors: examination of hematoporphyrin derivative distribution and long-term damage in rabbit ocular tissue. Cancer Res 1985; 45: 3718-3725.
36. Bellnier DA, Dougherty TJ. A preliminary pharmacokinetic study of intravenous Photofrin in patients. J Clin Laser Med Surg 1996; 14: 311-314.
37. Divaris DXG, Kennedy JC, Pottier RH. Phototoxic damage to sebaceous glands and hair follicles of mice after systemic administration of 5-aminolevulinic acid correlates with localized protoporphyrin Ix fluorescence. Am J Pathol 1990; 136: 891-897.
38. Kennedy JC, Pottier RH. Endogenous protoporphyrin IX, a clinically useful photosensitizer for photodynamic therapy. J Photochem Photobiol B 1992; 14: 275-292.
39. Kennedy JC, Pottier RH, Pross DC. Photodynamic therapy with endogenous protoporphyrin IX: basic principles and present clinical experience. J Photochem Photobiol B 1990; 6: 143-148.
40. Gomer CJ. Preclinical examination of first and second generation photosensitizers used in photodynamic therapy. Photochem Photobiol 1991; 54: 1093-1107.
41. Henderson BW, Dougherty TJ. How does photodynamic therapy work? Photochem Photobiol 1992; 55: 145-157.
42. De Rosa A, Di Luccia A, Rizzo A. Photodynamic therapy of tumors: New advances. ECCO 8, The European Conference. Paris, 29 October-2 November, 1995, Vol 31A Supplement 5, Publication n. 896.
43. Taylor EL, Brown SB. The advantages of aminolevulinic acid photodynamic therapy in dermatology. J Dermatol Treat 2002; 13(Suppl 1): S3-S11.
44. Korbelik M, Krosl G, Krosl J, et al. The role of host lymphoid populations in the response of mouse EMT6 tumor to photodynamic therapy. Cancer Res 1996; 56: 5647-5652.
45. Cecic I, Korbelik M. Mediators of peripheral blood neutrophilia induced by photodynamic therapy of solid tumors. Cancer Lett 2002; 183: 43-51.
46. Korbelik M. Induction of tumor immunity by photodynamic therapy. J Clin Laser Med Surg 1996; 14: 329-334.
47. Korbelik M, Krosl G. Enhanced macrophage cytotoxicity against tumor cells treated with photodynamic therapy. Photochem Photobiol 1994; 60: 497-502.
48. Korbelik M, Cecic I. Contribution of myeloid and lymphoid host cells to the curative outcome of mouse sarcoma treatment by photodynamic therapy. Cancer Lett 1999; 137: 91-98.
49. Granville DJ, McManus BM, Hunt DW. Photodynamic therapy: shedding light on the biochemical pathways regulating porphyrinmediated cell death. Histol Histopathol 2001; 16: 309-317.
50. Reed MW, Wieman TJ, Doak KW, et al. The microvascular effects of photodynamic therapy: evidence for a possible role of cyclooxygenase products. Photochem Photobiol 1989; 50: 419-423.
51. Fingar VH. Vascular effects of photodynamic therapy. J Clin Laser Med Surg 1996; 14: 323-328.
52. Foote CS. Definition of type I and type II photosensitized oxidation. Photochem Photobiol 1991; 54: 659.
53. Oleinick NL, Evans HH. The photobiology of photodynamic therapy: cellular targets and mechanisms. Radiat Res 1998; 150(5 Suppl): S146-S156.
54. Gomer CJ, Ferrario A, Hayashi N, et al. Molecular, cellular, and tissue responses following photodynamic therapy. Lasers Surg Med 1988; 8: 450-463.
55. Agarwal ML, Clay ME, Harvey EJ, et al. Photodynamic therapy induces rapid cell death by apoptosis in L5178Y mouse lymphoma cells. Cancer Res 1991; 51: 5993-5996.
56. Nakaseko H, Kobayashi M, Akita Y, et al. Histological changes and involvement of apoptosis after photodynamic therapy for actinic keratoses. Br J Dermatol 2003; 148: 122-127.
57. Matsumoto Y, Muro Y, Banno S, et al. Differential apoptotic pattern induced by photodynamic therapy and cisplatin in human squamous cell carcinoma cell line. Arch Dermatol Res 1996; 289: 52-54.
58. Verma A, Facchina SL, Hirsch DJ, et al. Photodynamic tumor therapy: mitochondrial benzodiazepine receptors as a therapeutic target. Mol Med 1998; 4: 40-45.
59. Granville DJ, Cassidy BA, Ruehlmann DO, et al. Mitochondrial release of apoptosis-inducing factor and cytochrome c during smooth muscle cell apoptosis. Am J Pathol 2001; 159: 305-311.
60. Granville DJ, Carthy CM, Jiang H, et al. Rapid cytochrome c release, activation of caspases 3, 6, 7 and 8 followed by Bap31 cleavage in HeLa cells treated with photodynamic therapy. FEBS Lett 1998; 437: 5-10.
61. Granville DJ, Levy JG, Hunt DW. Photodynamic therapy induces caspase-3 activation in HL-60 cells. Cell Death Differ 1997; 4: 623-628.
62. Porter AG, Janicke RU. Emerging role of caspase-3 in apoptosis. Cell Death Differ 1999; 6: 99-104.
63. He J, Agarwal ML, Larkin HE, et al. The induction of partial resistance to photodynamic therapy by the protooncogene BCL-2. Photochem Photobiol 1996; 64: 845-852.
64. Granville DJ, Jiang H, An MT, et al. Bcl-2 overexpression blocks caspase activation and downstream apoptotic events instigated by photodynamic therapy. Br J Cancer 1999; 79: 95-100.
65. Kim HR, Luo Y, Li G, et al. Enhanced apoptotic response to photodynamic therapy after bcl-2 transfection. Cancer Res 1999; 59: 3429-3432.
66. Zhou CN. Mechanisms of tumor necrosis induced by photodynamic therapy. J Photochem Photobiol B 1989; 3: 299-318.
67. Middelkamp-Hup MA, Sanchez-Carpintero I, Kossodo S, et al. Photodynamic therapy for cutaneous proliferative vascular tumors in a mouse model. J Invest Dermatol 2003; 121: 634-639.
68. Steluti R, De Rosa FS, Collett J, et al. Topical glycerol monooleate/propylene glycol formulations enhance 5-aminolevulinic acid in vitro skin delivery and in vivo protophorphyrin IX accumulation in hairless mouse skin. Eur J Pharm Biopharm 2005; 60: 439-444.
69. Bender J, Ericson MB, Merclin N, et al. Lipid cubic phases for improved topical drug delivery in photodynamic therapy. J Control Release 2005; 106: 350-360.
70. Ziolkowski P, Osiecka BJ, Oremek G, et al. Enhancement of photodynamic therapy by use of aminolevulinic acid/glycolic acid drug mixture. J Exp Ther Oncol 2004; 4: 121-129.
71. Korbelik M, Naraparaju VR, Yamamoto N. Macrophage-directed immunotherapy as adjuvant to photodynamic therapy of cancer. Br J Cancer 1997; 75: 202-207.
72. Korbelik M, Sun J, Posakony JJ. Interaction between photodynamic therapy and BCG immunotherapy responsible for the reduced recurrence of treated mouse tumors. Photochem Photobiol 2001; 73: 403-409.
73. Bellnier DA, Gollnick SO, Camacho SH, et al. Treatment with the tumor necrosis factor-alpha-inducing drug 5,6-dimethylxanthenone-4-acetic acid enhances the antitumor activity of the photodynamic therapy of RIF-1 mouse tumors. Cancer Res 2003; 63: 7584-7590.
74. Bellnier DA. Potentiation of photodynamic therapy in mice with recombinant human tumor necrosis factor-alpha. J Photochem Photobiol B 1991; 8: 203-210.
75. Ferrario A, von Tiehl KF, Rucker N, et al. Antiangiogenic treatment enhances photodynamic therapy responsiveness in a mouse mammary carcinoma. Cancer Res 2000; 60: 4066-4069.
76. Ferrario A, Chantrain CF, von Tiehl K, et al. The matrix metalloproteinase inhibitor prinomastat enhances photodynamic therapy responsiveness in a mouse tumor model. Cancer Res 2004; 64: 2328-2332.
77. Ferrario A, Von Tiehl K, Wong S, et al. Cyclooxygenase-2 inhibitor treatment enhances photodynamic therapy-mediated tumor response. Cancer Res 2002; 62: 3956-3961.
78. Korbelik M, Sun J, Cecic I, et al. Adjuvant treatment for complement activation increases the effectiveness of photodynamic therapy of solid tumors. Photochem Photobiol Sci 2004; 3: 812-816.
79. Maziere JC, Morliere P, Santus R: The role of the low density lipoprotein receptor pathway in the delivery of lipophilic photosensitizers in the photodynamic therapy of tumours. J. Photochem Photobiol B: Biol 1991; 8: 351-360.
80. Jori G, Beltrami M, Reddi E, Salvato B, Pagnan A, Ziron L, Tomlo L, Tsanov T: Evidence for a major role of plasma lipoproteins as hematoporphyrin carriers in vivo. Cancer Lett 1984; 24: 291-297.
81. Pottier R, Kennedy JC: The possible role of ionic species in selective biodistribution of photochemotherapeutic agents toward neoplastic tissue. J Photochem Photobiol B: Biol 1990; 8: 1-16.
82. Freitas I. Lipid accumulation, the common feature to photosensitizer-retaining normal and malignant tissues. J Photochem Photobiol B: Biol 1990; 7: 359-361.
83. Bugelski PJ, Porter CW, Dougherty TJ. Autoradiographic distribution of hematoporphyrin derivative in normal and tumor tissue of the mouse. Cancer Res 1981; 41: 4606-4612.
84. Jori G. In vivo transport and pharmacokinetic behaviour of tumour photosensitizers. In: Bock G, Hamett S (eds.) Photosensitizing Compounds: Their Chemistry, Biology and Clinical Use Ciba Foundation Symposia, Wiley, Chichester, 1989, pp. 78-86.
85. Korbelik M. Low density lipoprotein receptor pathway in the delivery of Photofrin: how much is it relevant for selective accumulation of the photosensitizer in tumors? J Photochem Photobiol B: Biol 1992; 12: 107-109.
86. Korbelik M, Krosl G, Olive PL, Chaplin DJ: Distribution of photofrin between tumor cells and tumor associated macrophages. Brit J Cancer 1991; 64: 508-512.
87. Milas L, Wike J, Hinter N, Volpe J, Basic I. Macrophage content of murine sarcomas and carcinomas: association with tumor growth parameters and tumor radiocurability. Cancer Rex 1987; 47: 1069-1075.
88. Kessel D, Luo Y. Photodynamic therapy: A mitochondrial inducer of apoptosis. Cell Death Differ 1999; 6: 28-35.
89. Morgan J, Oseroff AR. Mitochondria-based photodynamic anticancer therapy. Adv Drug Deliv Rev 2001; 49: 71-86.
90. Berg K, Moan J. Lysosomes and microtubules as targets for phototherapy of cancers. Photochem Photobiol 1997; 65: 403-409.
91. Carre V, Jayat C, Granet R, Krausz P, Guilloton M. Chronology of the apoptotic events induced in the K562 cell line by photodynamic treatment with hematoporphyrin and monoglucosylporphyrin. Photochem Photobiol 1999; 69: 55-60.
92. Ahmad N, Gupta S, Feyes DK, Mukhtar H. Involvement of Fas (APO-1/CD-95) during photodynamictherapy-mediated apoptosis in human epidermoid carcinoma A431 cells. J Invest Dermatol 2000; 115: 1041-1046.
93. Granville DJ, Jiang H, Mcmanus BM, Hunt DW: Fas ligand and TRAIL augment the effect of photodynamic therapy on the induction of apoptosis in JURKAT cells. Int Immunopharmacol 2001; 1: 1831-1840.
94. Granville DJ, Levy JG, Hunt DWC. Photodynamic therapy induces caspase-3 activation in HL-60 cells. Cell Death Differ 1997; 4: 623-628.
95. Srivastava M, Ahmad N, Gupta S, Mukhtar H. Involvement of Bcl-2 and Bax in photodynamic therapymediated apoptosis. Antisense Bcl-2 oligonucleotide sensitizes RIF 1 cells to photodynamic therapy apoptosis. J Biol Chem 2001; 276: 15481-15488.
96. Anderson P. Kinase cascades regulating entry into apoptosis. Microbiol Mol Biol Rev 1997; 61: 33-46.
97. Chan WH, Yu JS, Yang SD: Apoptotic signalling cascade in photosensitized human epidermal carcinoma A431 cells: involvement of singlet oxygen, c-Jun N-terminal kinase, caspase-3 and p21- activated kinase 2. Biochem J 2000; 351: 221-232.
98. Hasan T, Parrish JA. In: Cancer Medicine, 4th edition. Holland JF, Frei EI, Bast RCJ, Kufe DW, Morton DL, Weichselbaum RR (eds), Williams and Wilkins, Baltimore, 1996, pp 739-751.
99. Kessel D, Thomson P, Saatio K, Nantwi KD. Tumor localization and photosensitization by sulfonated derivatives of tetraphenylporphine. Photochem Photobiol 1987; 45: 787-789.
100. Dougherty TJ, Gomer CJ, Henderson BW, Jori G, Kessel D, Korbelik M, Moan J, Peng Q: Photodynamic therapy. J Natl Cancer Inst 1998; 90: 889-905.
101. Ali SM, Olivo M. Nitric oxide mediated photo-induced cell death in human malignant cells. Int J Oncol 2003; 22: 751-756.
102. von Tappeiner H, Jesionek H. Therapeutische versuche mit fluoreszierenden stoffen. Munch Med Wochenschr 1903; 47: 2042-2044.
103. von Tappeiner HA, Jodlbauer A. Die Sensibilisierende Wirkung Fluorescierender Substanzen: Gesammelte Untersuchungen Über die Photodynamische Erscheinung. Leipzig, Germany: F.C.W. Vogel, 1907: 1-210.
104. Dougherty TJ, Grindey GB, Fiel R et al. Photoradiation therapy. II. Cure of animal tumors with hematoporphyrin and light. J Natl Cancer Inst 1975; 55: 115-121.
105. Dougherty TJ, Kaufman JE, Goldfarb A et al. Photoradiation therapy for the treatment of malignant tumors. Cancer Res 1978; 38: 2628-2635.
106. Kelly JF, Snell ME. Hematoporphyrin derivative: a possible aid in the diagnosis and therapy of carcinoma of the bladder. J Urol 1976; 115: 150-151.
107. Henderson BW, Gollnick SO, Snyder JW., et al. Choice of oxygenconserving treatment regimen determines the inflammatory response and outcome of photodynamic therapy of tumors. Cancer Res 2004; 64: 2120-2126.
108. Morlet L, Vonarx-Coinsmann V, Lenz P et al. Correlation between meta (tetrahydroxyphenyl)chlorin (m-THPC) biodistribution and photodynamic effects in mice. Photochem Photobiol 1995; 28: 25-32.
109. Veenhuizen RB, Ruevekamp MC, Oppelaar H et al. Foscanmediated photodynamic therapy for a peritoneal-cancer model: drug distribution and efficacy studies. Int J Cancer 1997; 73: 230-235.
110. Ris HB, Altermatt HJ, Stewart CM et al. Photodynamic therapy with mtetrahydroxyphenylchlorin in vivo: optimization of the therapeutic index. Int J Cancer 1993; 55: 245-249.
111. Chen B, de Witte PA. Photodynamic therapy efficacy and tissue distribution of hypericin in a mouse P388 lymphoma tumor model. Cancer Lett 2000; 150: 111-117.
112. Cramers P, Ruevekamp M, Oppelaar H., et al. Foscan uptake and tissue distribution in relation to photodynamic efficacy. Br J Cancer 2003; 88: 283-290.
113. Triesscheijn M, Ruevekamp M, Aalders M et al. Outcome of mTHPC mediated photodynamic therapy is primarily determined by the vascular response. Photochem Photobiol 2005; 81: 1161-1167.
114. Veenhuizen R, Oppelaar H, Ruevekamp M et al. Does tumour uptake of Foscan determine PDT efficacy? Int J Cancer 1997; 73: 236-239.
115. Chen B, Pogue BW, Goodwin IA et al. Blood flow dynamics after photodynamic therapy with verteporfin in the RIF-1 tumor. Radiat Res 2003; 160: 452-459.
116. Henderson BW, Waldow SM, Mang TS et al. Tumor destruction and kinetics of tumor cell death in two experimental mouse tumors following photodynamic therapy. Cancer Res 1985; 45: 572-576.
117. Star WM, Marijnissen HPA, van den Berg-Blok AE et al. Destruction of rat mammary tumor and normal tissue microcirculation by hematoporphyrin derivative photoradiation observed in vivo in sandwich observation chambers. Cancer Res 1986; 46: 2532-2540.
118. van Geel IP, Oppelaar H, Oussoren YG et al. Changes in perfusion of mouse tumours after photodynamic therapy. Int J Cancer 1994; 56: 224-228.
119. van Geel IP, Oppelaar H, Rijken PF et al. Vascular perfusion and hypoxic areas in RIF-1 tumours after photodynamic therapy. Br J Cancer 1996; 73: 288-293.
120. de Vree WJ, Essers MC, de Bruijn HS et al. Evidence for an important role of neutrophils in the efficacy of photodynamic therapy in vivo. Cancer Res 1996; 56: 2908-2911.
121. Fingar VH, Siegel KA, Wieman TJ et al. The effects of thromboxane inhibitors on the microvascular and tumor response to photodynamic therapy. Photochem Photobiol 1993; 58: 393-399.
122. Henderson BW, Sitnik-Busch TM, Vaughan LA. Potentiation of photodynamic therapy antitumor activity in mice by nitric oxide synthase inhibition is fluence rate dependent. Photochem Photobiol 1999; 70: 64-71.
123. Hendrzak-Henion JA, Knisely TL, Cincotta L et al. Role of the immune system in mediating the antitumor effect of benzophenothiazine photodynamic therapy. Photochem Photobiol 1999; 69: 575-581.
124. Korbelik M, Cecic I. Contribution of myeloid and lymphoid host cells to the curative outcome of mouse sarcoma treatment by photodynamic therapy. Cancer Lett 1999; 137: 91-98.
125. Wilson PC. Photosensitizing Compounds: Their Chemistry, Biology and Clinical Use; 1989 Wiley Interscience: Chichster, 73.
126. Wainwright M: Non-porphyrin photosensitizers in biomedicine. Chem Soc Rev 1996; 25: 351-451.
127. Woodburn K, Chang CK, Sangwan L, Henderson B, Kessel D: Biodistribution and PDT efficacy of a ketochlorin photosensitizer as a function of the delivery vehicle. Photochem Photobiol 1994; 60: 154-159.
128. Mahley RW, Innerarity TL. Lipoprotein receptors and cholesterol homeostasis. Biochim Biophys Acta 1983; 737(2): 197-222.
129. Bonnett R. Photosensitizers of the porphyrin and phtalocyanine series for photodynamic therapy. Chem. Soc. Rev 1995; 24: 19-33.
130. Scourides PS, Böhmer RM, Kaye AH, Morstyn G. Nature of the tumor-localizing components of hematoporphyrin derivative. Canc Res 1987; 47: 3439-3445.
131. Da Costa G, Chevance S, Le Rumeur E, Bondon A. Proton NMR detection of porphyrins and cytochrome c in small unilamellar vesicles: role of the dissociation kinetic constant. Biophysical Journal: Biophysical Letters 2006; L55-L57.
132. Netland P.A., Zetter BR, Via DP, Voyta JC. In situ labeling of vascular endothelium with fluorescent acetylated low density lipoprotein. Histochemical Journal 1985; 17: 1309-1320.
133. Gueddari N, Favre G, Hachem H, Marek E, Legaillard F, Soula G: Evidence for up-regulated low-density lipoprotein receptor in human lung adenocarcinoma cell line-A549. Biochimie 1993; 75: 811-819.
134. Manning F. Review of the epidemiological evidence for a possible relationship between hypocholesterolemia and cancer. Cancer Res 1983; 43: 2503s-2507s.
135. Vitols S, Gahrton G, Ost A, Peterson C. Elevated low density lipoprotein receptor activity in leukemic cells with monocytic differentiation. Blood 1984; 5: 1186-1193.
136. Brunner H, Schellerer KM. New porphyrin platinum conjugates for the cytostatic and photodynamic tumor therapy. Inorg. Chim. Acta 2003; 39-48.
137. Gencheva G, Tsekova D, Gochev G, Momekov G, Tyulliev G, Skumryev V, Karaivanova M, Bontchev PR. Synthesis, structural characterization, and cytotoxic activity of novel paramagnetic platinum hematoporphyrin IX Complexes: potent antitumor agents. Metal Based Drugs 2007; article ID 67376, 13 pages.